Open access
Jul 2026
THE NEXT FRONTIER OF INDIAN PHARMA: BIOLOGICS AND ADVANCED THERAPEUTICS
The recent BioE3 policy and Biopharma SHAKTI initiative, with its Rs.10,000/- crore outlay signals a definitive pivot from volume driven growth to value driven innovations in the move to much needed affordable next generation biologics.
Papia Saraf
· Indian drugs · 0 citations